Background: The aim of this study was to compare the effects of olanzapine versus haloperidol to control the signs and symptoms of stuttering.
Methods: Ninety-three patients were recruited in a 12-week single-blind randomized clinical trial, which was held between October 2009 and October 2010. Forty-three patients received olanzapine (5 mg/day) and 50 patients, haloperidol (2.5 mg/day). Before and after the study, they were evaluated by a speech pathologist by Van Riper's questionnaire. The data were analyzed using the SPSS version 16. T-test was used to compare the data between the two groups.
Results: Mean of stuttering score (SD) before treatment was 4.67 (0.81) and 4.40 (1.14) in haloperidol and olanzapine groups, respectively (P > 0.05). After treatment, the mean (SD) score was 2.87 (1.32) and 1.56 (0.71) in haloperidol and olanzapine groups, respectively (P = 0.000).
Conclusions: It seems that olanzapine does have better impact in controlling stuttering, and it may be recommended to prescribe olanzapine for stutters as the first choice to control the stuttering under a careful follow-up.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678230 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Comparative Efficacy of Novel Versus Traditional Antiemetic Agents in Preventing Chemotherapy-Induced Nausea and Vomiting With Moderate or Highly Emetogenic Chemotherapy: A Systematic Review.
Cureus
October 2024
Department of Internal Medicine, Allama Iqbal Medical College, Lahore, PAK.
Article Synopsis
- The review analyzes the effectiveness of new antiemetic medications versus traditional ones for preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing moderate or highly emetogenic chemotherapy.
- It finds that novel agents like netupitant/palonosetron and olanzapine are at least as effective, if not better, than standard antiemetic treatments that use aprepitant and other agents.
- The study calls for more direct comparisons and larger trials to further understand the benefits of these new therapies in everyday clinical practice.
Comparing the cardiorespiratory safety of parenteral olanzapine and benzodiazepines to parenteral haloperidol/droperidol and benzodiazepines in emergency department patients.
Am J Emerg Med
January 2025
Upstate University Hospital, Department of Pharmacy, 750 East Adams Street, Syracuse, NY, USA.
Introduction: This study sought to assess the cardiorespiratory safety of parenteral olanzapine and benzodiazepine combination treatment compared to parenteral droperidol or haloperidol and benzodiazepine combination treatment.
Materials And Methods: This was a retrospective chart review conducted in adult emergency department patients who received intramuscular (IM) or intravenous (IV) droperidol, haloperidol, or olanzapine within one hour of IM or IV benzodiazepine. Patients were stratified into groups based on whether they received either olanzapine in combination with a benzodiazepine (n = 48) or droperidol or haloperidol in combination with a benzodiazepine (n = 48).
Effects of olanzapine in the improvement of body weight and appetite in patients with cancer or receiving chemotherapy: a systematic review and meta-analysis.
Eur J Clin Pharmacol
January 2025
The Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Objective: We aimed to assess the effects of olanzapine in the improvement of body weight and appetite in patients with cancer or receiving chemotherapy through a systematic review and meta-analysis.
Methods: We searched the following databases from their inception to April 23, 2024: Embase, PubMed, Web of Science, and the Cochrane Library. The mean difference (MD) and risk ratios were used to calculate by random effects models.
Olanzapine Versus Quetiapine: Corrected QT Changes in Critically Ill Patients.
Ann Pharmacother
October 2024
Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.
Article Synopsis
- This study compares the effects of olanzapine and quetiapine on QTc prolongation in critically ill patients, as prior research in this area is limited.
- The analysis included patients in the ICU who received at least two doses of either medication and assessed QTc changes within 48 hours.
- Results indicated no significant differences in QTc prolongation between the two drugs, suggesting that they may have similar safety profiles for this condition in an ICU setting.*
A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia.
Schizophr Res
December 2024
Institute for Clinical and Economic Review, Boston, MA, United States of America.
Background: Dopaminergic antipsychotics for schizophrenia have modest effects on symptoms and can cause important side effects. KarXT is an investigational drug for schizophrenia with a novel mechanism targeting muscarinic receptors that may limit these side effects.
Methods: We conducted a systematic review and Bayesian random-effects network meta-analyses of short-term RCTs (3-8 weeks) that enrolled adults with schizophrenia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!